Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance)

BACKGROUND: This multicenter, randomized phase 2 trial evaluated complete response (CR), efficacy, and safety with ofatumumab and bendamustine and ofatumumab, bendamustine, and bortezomib in patients with untreated, high-risk follicular lymphoma (FL). METHODS: Patients with grade 1–3a FL and either...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Blum, Kristie A., Polley, Mei-Yin, Jung, Sin-Ho, Dockter, Travis J., Anderson, Sarah, Hsi, Eric D., Wagner-Johnston, Nina, Christian, Beth, Atkins, Jim, Cheson, Bruce D., Leonard, John P., Bartlett, Nancy L.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6744328/
https://ncbi.nlm.nih.gov/pubmed/31174236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32289
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items